1. Home
  2. TBPH vs WSR Comparison

TBPH vs WSR Comparison

Compare TBPH & WSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • WSR
  • Stock Information
  • Founded
  • TBPH 2013
  • WSR 1998
  • Country
  • TBPH United States
  • WSR United States
  • Employees
  • TBPH N/A
  • WSR N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • WSR Real Estate Investment Trusts
  • Sector
  • TBPH Health Care
  • WSR Real Estate
  • Exchange
  • TBPH Nasdaq
  • WSR Nasdaq
  • Market Cap
  • TBPH 699.0M
  • WSR 628.6M
  • IPO Year
  • TBPH N/A
  • WSR 2010
  • Fundamental
  • Price
  • TBPH $14.75
  • WSR $13.23
  • Analyst Decision
  • TBPH Strong Buy
  • WSR Strong Buy
  • Analyst Count
  • TBPH 4
  • WSR 2
  • Target Price
  • TBPH $23.00
  • WSR $15.00
  • AVG Volume (30 Days)
  • TBPH 284.3K
  • WSR 205.4K
  • Earning Date
  • TBPH 11-10-2025
  • WSR 10-29-2025
  • Dividend Yield
  • TBPH N/A
  • WSR 4.30%
  • EPS Growth
  • TBPH N/A
  • WSR 108.75
  • EPS
  • TBPH 0.26
  • WSR 0.86
  • Revenue
  • TBPH $77,205,000.00
  • WSR $157,788,000.00
  • Revenue This Year
  • TBPH $79.82
  • WSR $0.95
  • Revenue Next Year
  • TBPH N/A
  • WSR $4.70
  • P/E Ratio
  • TBPH $59.49
  • WSR $14.65
  • Revenue Growth
  • TBPH 24.49
  • WSR 5.59
  • 52 Week Low
  • TBPH $7.90
  • WSR $11.43
  • 52 Week High
  • TBPH $15.34
  • WSR $15.36
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 58.51
  • WSR 67.11
  • Support Level
  • TBPH $14.11
  • WSR $12.32
  • Resistance Level
  • TBPH $15.34
  • WSR $13.02
  • Average True Range (ATR)
  • TBPH 0.42
  • WSR 0.27
  • MACD
  • TBPH 0.06
  • WSR 0.13
  • Stochastic Oscillator
  • TBPH 63.55
  • WSR 66.87

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About WSR Whitestone REIT

Whitestone REIT is a real estate investment trust (REIT) engaged in owning and operating commercial properties in culturally diverse markets in metropolitan areas. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business friendly locations in and around Austin, Chicago, Dallas-Fort Worth, Houston, Phoenix, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.

Share on Social Networks: